X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Essa pharma announces results from the phase 1 clinical trial of epi-506 for treatment of mcrpc

Yuvraj_pawp by Yuvraj_pawp
11th September 2017
in Clinical Trials

ESSA Pharma Inc. , a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, today announced that results from the Phase 1 portion of the Phase 1/2 clinical trial of EPI-506 for the treatment of metastatic castrationresistant prostate cancer (“mCRPC”) were presented at the European Society for Medical Oncology (“ESMO”) held in Madrid, Spain. EPI-506 (ralaniten acetate) is a first generation N-terminal domain inhibitor of the androgen receptor (AR-NTD).

The open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum tolerated dose, and anti-tumor activity of EPI-506 in men with end-stage mCRPC who have progressed after prior enzalutamide and/or abiraterone treatment and may have received one prior line of chemotherapy. Twenty-eight patients were available for analysis and each patient had received four or more prior therapies for prostate cancer at the time of study entry. Patients self-administered oral doses of EPI-506 ranging from 80 mg to 3600 mg, with mean drug exposure of 85 days (range of eight to 535 days). Four patients have undergone prolonged treatment (median of 318 days; range 219 to 535 at data cut-off), following intrapatient dose escalation. Prostate-specific antigen (“PSA”) declines ranging from 4% to 29% were observed in five patients, which occurred predominantly in the higher dose cohorts (≥1280 mg).

EPI-506 was generally well-tolerated with a favorable safety profile across all doses up to 2400 mg. At a dose of 3600 mg, gastrointestinal adverse events (nausea, vomiting, abdominal pain) were observed in two patients: one patient in the once-daily (“QD”) dosing cohort and one patient in the 1800 mg twicedaily dosing cohort, leading to study discontinuation and dose-limiting toxicity (“DLT”) due to >25% missed doses in the 28-day safety reporting period. A separate patient in the 3600 mg QD cohort experienced a transient Grade 3 increase in liver enzymes (AST/ALT), which also constitutes a DLT, so enrollment was concluded in that cohort.

“Signs of efficacy at higher-dose levels in this open-label Phase 1 clinical trial, combined with the overall safety profile, indicate that our unique approach of inhibiting the Androgen Receptor N-terminal domain may provide a clinical benefit to mCRPC patients,” said Frank Perabo, M.D., Ph.D. and Chief Medical Officer at ESSA.

While the clinical profile of EPI-506 or its active metabolite, EPI-002, could potentially be enhanced through reformulation efforts, ESSA believes that prioritizing development of one of its next-generation NTD inhibitors (“Aniten”) with greater potency and other enhanced pharmaceutical properties offers the most compelling regulatory and commercial pathway. As a result, ESSA will discontinue further clinical development of EPI-506 and will implement a corporate restructuring plan to focus R&D resources on its next-generation Anitens targeting the AR-NTD.

“We were encouraged by the data from the Phase 1 portion of the Phase 1/2 clinical trial and are pleased to have established the safety and clinical utility of targeting the N-terminal domain (“NTD”) in refractory mCRPC patients,” said David Parkinson, M.D., President and Chief Executive Officer of ESSA. 

“Our next-generation Aniten program is structurally similar to EPI-506 and has the potential to deliver increased potency and an improved pharmacological profile, so it represents a more favorable value proposition for ESSA. We look forward to shifting our focus to advance the Company’s promising Aniten program.”

ESSA’s next-generation Aniten compounds represent a new class of drugs that are NTD inhibitors of the androgen receptor (“AR”) and are designed to improve upon a number of attributes of first-generation compound, EPI-506. The next-generation Anitens are considerably more potent than EPI-506 or its active metabolite, EPI-002, in an in vitro assay measuring inhibition of AR transcriptional activity. In addition, the compounds are designed to improve upon the pharmaceutical properties of EPI-506 to enable a more efficient and cost-effective formulation approach.

The Aniten program is currently at the Investigational New Drug (“IND”) lead-selection stage with an IND filing expected to occur in early 2019. The corporate restructuring associated with ESSA’s updated clinical plan is expected to lower cash expenditures in fiscal 2018 by approximately US$7 million relative to fiscal 2017, resulting primarily from the discontinuation of EPI-506 clinical costs. As previously reported, the Company ended June 30, 2017 with $7.2 million in cash, cash equivalents and short-term investments, and anticipates that its current resources are sufficient to support planned operations into the fourth calendar quarter of 2017.

“I would like to personally express my appreciation to each of the employees impacted by this decision for their commitment to ESSA and the EPI-506 program as well as the patients and clinical investigators who helped define the properties of this new class of drug,” continued Dr. Parkinson. “The results of their efforts will drive further development in this important area of clinical need as we reallocate our resources to the Aniten program.”

ESSA wishes to remind investors that Dr. Parkinson will be presenting at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City today at 4:15 PM Eastern Standard Time, at the Lotte New York Palace Hotel. To access the live webcast, please visit www.wsw.com/webcast/rrshq27/epi/

 

About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of CRPC in patients whose disease is progressing despite treatment with current therapies. ESSA believes that its proprietary compounds can significantly expand the interval of time in which patients suffering from CRPC can benefit from hormone-based therapies, by disrupting the AR signaling pathway that drives prostate cancer growth and by preventing AR transcriptional activity by binding selectively to the NTD of the AR. A functional NTD is essential for transactivation of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known ARdependent
mechanisms of CRPC. ESSA was founded in 2009.

Peter A. Virsik
Chief Operating Officer
Tel: (832) 831-5958

David S. Wood
Chief Financial Officer
Tel: (778) 331-0962

Previous Post

TrakCel announces a partnership agreement to incorporate its needle-to-needle supply chain management platform into the CGT Catapult’s large-scale cell and gene therapy manufacturing centre.

Next Post

Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management

Related Posts

Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer
Clinical Trials

Major Success Factors For Clinical Development Organizations

12th April 2022
ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East
Clinical Trials

ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

8th April 2022
Takara Bio and Boston IVF Fertility Center Announce Partnership to Enable the Derivation of Clinical-grade hES cell lines for Cell Therapy Applications
Clinical Trials

Calyx Selected by ProTrials as Partner for Improving Clinical Trial Outcomes Data

22nd March 2022
Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials
Clinical Trials

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

7th February 2022
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
Clinical Trials

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

7th February 2022
Qatar approves emergency use of Modernas COVID-19 vaccine
Clinical Trials

Moderna Starts Variant Specific Vaccine Trials After Pfizer

28th January 2022
Next Post

Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In